About TURBOVAX, INC.
TurboVax Inc. is a Delaware C-corporation founded in 2023 by Dr. Kishore R. Alugupalli, focused on developing a novel adjuvant platform called Turbo for bacterial glycoconjugate and protein subunit vaccines to improve immunogenicity and reduce the need for multiple doses.
Development of Turbo, an adjuvant formulation targeting B cell-centric functions for efficient immune responsesTesting of Turbo's adjuvanticity with FDA-approved and WHO-prequalified bacterial glycoconjugate vaccines and hapten-coupled proteinsCreation of single-dose glycoconjugate vaccines with Turbo-adjuvanted formulations
Is this your company?
Claim TURBOVAX, INC. to unlock the federal & state contracts GovIntel's AI has matched to you right now — plus your own scored past-performance, who you're up against, and who's risky to team with.
Claim TURBOVAX, INC. & see your matchesFree to claim. Takes about a minute.
Data compiled from public government sources including SAM.gov, USAspending.gov, and state procurement records. Last verified against federal award records. Inaccurate, or want this page removed? Request a correction or removal.